[Cost-effectiveness analysis of treatment for end-stage renal disease]
- PMID: 19996463
[Cost-effectiveness analysis of treatment for end-stage renal disease]
Abstract
Objective: End-stage renal disease (ESRD) requires costly life-sustaining therapy, either dialysis or kidney transplantation. The purpose of this study was to analyse and compare the cost-effectiveness of kidney transplantation and dialysis in Iceland.
Material and methods: Costs and effectiveness were assessed using the clinical records of the Division of Nephrology patient registration and billing systems and at Landspitali University Hospital, information from the Icelandic Health Insurance on payments for kidney transplantation at Rigshospitalet in Copenhagen, and published studies on survival and quality of life among patients with ESRD. All costs are presented at the 2006 price level and discounting was done according to the lowest interest rate of the Icelandic Housing Finance Fund in that year.
Results: The cost associated with live donor kidney transplantation was greater in Denmark than at LUH, ISK 6.758.101 and ISK 5.442.763, respectively. The cost per quality-adjusted life year gained by live donor kidney transplantation was approximately ISK 2.5 million compared to ISK 10.7 million for dialysis.
Conclusion: The cost of live donor kidney transplantation is within the range generally considered acceptable for life-sustaining therapies. The transplant surgery is less expensive in Iceland than in Denmark. Increasing the number of kidney transplants is cost-effective in light of the lower cost per life-year gained by kidney transplantation compared to dialysis.
Comment in
-
[Health, quality of live and money. Using cost-effectiveness analysis for setting health priorities].Laeknabladid. 2009 Nov;95(11):743. Laeknabladid. 2009. PMID: 19996461 Icelandic. No abstract available.
Similar articles
-
Variations in living donor graft rates by dialysis clinic: effect on outcome and cost of chronic renal failure therapy.Clin Nephrol. 1997 Jun;47(6):351-5. Clin Nephrol. 1997. PMID: 9202863
-
Economic evaluation of sevelamer in patients with end-stage renal disease.Nephrol Dial Transplant. 2007 Oct;22(10):2867-78. doi: 10.1093/ndt/gfm367. Epub 2007 Jun 25. Nephrol Dial Transplant. 2007. PMID: 17595182
-
Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.Health Econ. 2003 Nov;12(11):949-58. doi: 10.1002/hec.790. Health Econ. 2003. PMID: 14601157
-
[Clinical results of the various replacement therapies for chronic renal failure: haemodialysis and renal transplantation].G Ital Nefrol. 2004 Jan-Feb;21 Suppl 26:S3-9. G Ital Nefrol. 2004. PMID: 15732042 Review. Italian.
-
Is living kidney donation the answer to the economic problem of end-stage renal disease?Semin Nephrol. 2009 Sep;29(5):533-8. doi: 10.1016/j.semnephrol.2009.06.010. Semin Nephrol. 2009. PMID: 19751899 Review.
Cited by
-
Kidney transplantation in Icelandic patients, 2000-2019: are outcomes affected by low volume?Front Transplant. 2024 May 28;3:1398444. doi: 10.3389/frtra.2024.1398444. eCollection 2024. Front Transplant. 2024. PMID: 38993778 Free PMC article.
-
Retrograde reperfusion of renal grafts to reduce ischemic-reperfusion injury.Korean J Transplant. 2022 Dec 31;36(4):253-258. doi: 10.4285/kjt.22.0053. Korean J Transplant. 2022. PMID: 36704809 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical